FDA Issues Class I Recall for Boston Scientific Carotid Stent

What Happened: Scope & Rationale

On August 22, 2025, the FDA classified as Class I the recall of Boston Scientific’s Carotid WALLSTENT Monorail Endoprosthesis, a self-expanding stent used to treat carotid artery narrowing U.S. Food and Drug Administration Cardiovascular Business.

Affected models (over 26,000 globally, including 1,333 in the U.S.) were found to have a manufacturing defect: their inner delivery lumen was narrower than specified, causing resistance during device withdrawal MedTech Dive Cardiovascular Business. Such resistance could lead to vascular injury, stent damage, or embolization of debris, potentially resulting in a stroke—the most serious risk noted MedTech Dive Cardiovascular Business tctmd.com.

Boston Scientific alerted customers with an Urgent Medical Device Removal Letter on July 7, 2025, urging immediate cessation of use, segregation of affected inventory, and product return U.S. Food and Drug Administration MedTech Dive. As of July 29, 2025, six cases required additional intervention due to device retrieval issues, though no deaths have been reported U.S. Food and Drug Administration MedTech Dive tctmd.com.

Clinical Trial Background: Safety & Efficacy

BEACH Trial Overview

The BEACH trial (Boston Scientific EPI: A Carotid Stenting Trial for High-Risk Patients) was a prospective, single-arm, multicenter study with 747 patients (480 pivotal, 189 roll-in, 78 bilateral registry) designed to evaluate the safety and efficacy of the Carotid WALLSTENT combined with the FilterWire EZ embolic protection system in high-surgical-risk patients (symptomatic ≥50% stenosis or asymptomatic ≥80%) FDA Access Data ScienceDirect.

Primary endpoint: 1-year morbidity and mortality—including death, stroke, non-Q-wave MI, late ipsilateral stroke, and neurologic death.

Result: The observed rate was 8.9%, with the upper 95% confidence limit below the non-inferiority threshold of 16.6%, demonstrating that the device is non-inferior to carotid endarterectomy in this population ScienceDirect FDA Access Data.

Adverse Events Summary

Major adverse events: Most strokes were minor or ipsilateral; ipsilateral stroke at 1-year was ~5.5%, major ischemic strokes were low ScienceDirect FDA Access Data.
Serious adverse events (SAEs): Occurred in 52.3% of patients over 360 days—common categories included vascular/dissection, procedural complications, cardiac, and neurologic events ScienceDirect FDA Access Data.
Deaths: Spread across neurologic, cardiac, respiratory, and other causes, mostly within expected ranges for high-risk patients ScienceDirect FDA Access Data.

These results supported the device’s FDA approval in 2008, establishing its role for patients ineligible for surgery Boston Scientific FDA Access Data.

Pharmacovigilance & Public Health Implications

Pharmacovigilance Impact

The recall underscores the critical role of post-market surveillance, even for devices with strong trial data.
The defect highlights that manufacturing quality systems must remain rigorous after approval; deviations can introduce new safety risks unrelated to clinical performance.
Rapid detection of six adverse retrieval events reflects robust vigilance across the healthcare system and emphasizes early recognition of atypical device behavior.

Public Health & Real-World Data Considerations

Though the recall affects a relatively small proportion of devices, the potential stroke risk elevates its significance—especially in settings where surgical alternatives may not exist.
For existing implants that were deployed successfully, there’s no change in post-procedure management—standard care continues unless complications arise TGA.
Clinics must adjust inventory practices, potentially facing short-term procedural delays or need to switch devices, impacting access to treatment.
Trust in device safety relies on transparent regulatory action and company responsiveness—prompt removal and tracking forms help maintain confidence.

Summary Table

Category	Key Points
Recall Overview	Class I recall; resistant withdrawal risk; six recoveries; no deaths.
BEACH Trial Data	747 patients; 1-yr morbidity/mortality 8.9%; non-inferior to surgery.
Adverse Event Profile	SAEs in 52%; strokes and deaths within trial expectations.
Pharmacovigilance	Real-world signal detection is vital; quality systems critical post-approval.
Public Health Impact	Stroke risk concern; care for existing implants unchanged; supply implications.

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.